

1 **Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA**  
2 **vaccination with a sixteen-week interval between doses**

3 Alexandra Tauzin<sup>1,2</sup>, Shang Yu Gong<sup>1,3</sup>, Guillaume Beaudoin-Bussi eres<sup>1,2</sup>, Dani V ezina<sup>1</sup>, Romain  
4 Gasser<sup>1,2</sup>, Lauriane Nault<sup>1,2</sup>, Lorie Marchitto<sup>1,2</sup>, Mehdi Benlarbi<sup>1</sup>, Debashree Chatterjee<sup>1</sup>, Manon  
5 Nayrac<sup>1,2</sup>, Annemarie Laumaea<sup>1,2</sup>, J er emie Pr evost<sup>1,2</sup>, Marianne Boutin<sup>1,2</sup>, G er emy Sannier<sup>1,2</sup>,  
6 Alexandre Nicolas<sup>1,2</sup>, Catherine Bourassa<sup>1</sup>, Gabrielle Gendron-Lepage<sup>1</sup>, Halima Medjahed<sup>1</sup>,  
7 Guillaume Goyette<sup>1</sup>, Yuxia Bo<sup>4</sup>, Jos ee Perreault<sup>5</sup>, Laurie Gokool<sup>1</sup>, Chantal Morrisseau<sup>1</sup>, Pascale  
8 Arlotto<sup>1</sup>, Ren ee Bazin<sup>5</sup>, Mathieu Dub e<sup>1</sup>, Gaston De Serres<sup>6</sup>, Nicholas Brousseau<sup>6</sup>, Jonathan  
9 Richard<sup>1,2</sup>, Roberta Rovito<sup>7</sup>, Marceline C ot e<sup>4</sup>, C ecile Tremblay<sup>1,2</sup>, Giulia C. Marchetti<sup>7</sup>, Ralf Duerr<sup>8</sup>,  
10 Val erie Martel-Laferrierre<sup>1,2,7</sup>, Daniel E. Kaufmann<sup>1,9,\*</sup>, and Andr es Finzi<sup>1,2,3,10,\*</sup>

11 <sup>1</sup>Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada

12 <sup>2</sup>D epartement de Microbiologie, Infectiologie et Immunologie, Universit e de Montr al, Montreal, QC, H2X  
13 0A9, Canada

14 <sup>3</sup>Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada

15 <sup>4</sup>Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and  
16 Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada

17 <sup>5</sup>H ema-Qu ebec, Affaires M edicales et Innovation, Quebec, QC G1V 5C3, Canada

18 <sup>6</sup>Institut National de Sant e Publique du Qu ebec, Quebec, QC, H2P 1E2, Canada

19 <sup>7</sup>Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of  
20 Milan, Milan, Italy.

21 <sup>8</sup>Department of Microbiology, New York University School of Medicine, New York, NY, 10016, USA

22 <sup>9</sup>D epartement de M edecine, Universit e de Montr al, Montreal, QC, H3T 1J4, Canada

23

24

25 <sup>10</sup>Lead contact

26 \*Correspondence: [valerie.martel-laferrierre.med@sss.gouv.qc.ca](mailto:valerie.martel-laferrierre.med@sss.gouv.qc.ca) (V.M.L.),

27 [daniel.kaufmann@umontreal.ca](mailto:daniel.kaufmann@umontreal.ca) (D.E.K.), [andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca) (A.F.)

28

29 Summary word count: **133**

30

31 Character count: **42258**

## 32 **SUMMARY**

33 While the standard regimen of the BNT162b2 mRNA vaccine includes two doses  
34 administered three weeks apart, some public health authorities decided to space them, raising  
35 concerns about vaccine efficacy. Here, we analyzed longitudinal humoral responses including  
36 antibody binding, Fc-mediated effector functions and neutralizing activity against the D614G strain  
37 but also variants of concern and SARS-CoV-1 in a cohort of SARS-CoV-2 naïve and previously  
38 infected individuals, with an interval of sixteen weeks between the two doses. While the  
39 administration of a second dose to previously infected individuals did not significantly improve  
40 humoral responses, we observed a significant increase of humoral responses in naïve individuals  
41 after the 16-weeks delayed second shot, achieving similar levels as in previously infected  
42 individuals. Our results highlight strong vaccine-elicited humoral responses with an extended  
43 interval BNT162b2 vaccination for naïve individuals.

44

45 **KEYWORDS:** Coronavirus, COVID-19, SARS-CoV-2, Spike glycoproteins, Delayed mRNA  
46 vaccine regimen, Variants of concern, Variants of interest, Humoral responses, Neutralization,  
47 ADCC

## 48 INTRODUCTION

49 Since the end of 2019, the etiological agent of the Coronavirus disease 2019 (COVID-19),  
50 the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has spread worldwide  
51 causing the current pandemic (Dong et al., 2020; World Health Organization). In the last months,  
52 several vaccines against SARS-CoV-2 have been approved in many countries, including the  
53 Pfizer/BioNtech BNT162b2 mRNA vaccine. This vaccine targets the highly immunogenic trimeric  
54 Spike (S) glycoprotein that facilitates SARS-CoV-2 entry into host cells via its receptor-binding  
55 domain (RBD) that interacts with angiotensin-converting enzyme 2 (ACE-2) (Hoffmann et al.,  
56 2020; Walls et al., 2020) and has shown an important vaccine efficacy (Polack et al., 2020;  
57 Skowronski and De Serres, 2021).

58 The approved BNT162b2 mRNA vaccine regimen comprises two doses administered 3-4  
59 weeks apart (WHO, 2021). However, at the beginning of the vaccination campaign (Winter/Spring  
60 2021) vaccine scarcity prompted some public health agencies to extend the interval between  
61 doses in order to maximize the number of immunized individuals. This strategy was supported by  
62 results indicating that a single dose affords ~90% protection starting two weeks post vaccination,  
63 concomitant with the detection of some vaccine-elicited immune responses (Baden et al., 2021;  
64 Pilishvili, 2021; Polack et al., 2020; Skowronski and De Serres, 2021; Tauzin et al., 2021).

65 The rapid emergence of several variants of concerns (VOCs) and variants of interest (VOIs),  
66 which are more transmissible and in some cases more virulent (Allen et al., 2021; Brown et al.,  
67 2021; Davies et al., 2021; Fisman and Tuite, 2021; Pearson et al., 2021) remains a major public  
68 health preoccupation as the vaccine campaign advances worldwide. For example, the mutation  
69 D614G in the S glycoprotein which appeared very early in the pandemic is now present in almost  
70 all circulating strains (Isabel et al., 2020). The B.1.1.7 (Alpha) variant emerged in late 2020 in the  
71 United Kingdom and due to its increased affinity for the ACE2 receptor that leads to increased  
72 transmissibility (Davies et al., 2021), it became in just a few months a predominant strain

73 worldwide (Davies et al., 2021; Prévost et al., 2021; Rambaut et al., 2020). The B.1.351 (Beta)  
74 and P.1 (Gamma) variants that first emerged in South Africa and Brazil respectively have largely  
75 spread and are now circulating in many countries (ECDC, 2021; Tang et al., 2021). The B.1.526  
76 (Iota) variant first identified in New York in early 2021 (Annavajhala et al., 2021a) is in an upward  
77 trajectory in the United States (Annavajhala et al., 2021b). More recently, the B.1.617.2 (Delta)  
78 variant which emerged in India and has a high transmissibility is now the dominant strain in several  
79 countries (Allen et al., 2021; Dagpunar, 2021). Although several studies have shown that mRNA  
80 vaccines protect against severe disease caused by these variants, it has also been shown that  
81 some of them present resistance to some vaccine-elicited immune responses, notably against  
82 neutralizing antibodies (Annavajhala et al., 2021a; Goel et al., 2021a; Planas et al., 2021a;  
83 Puranik et al., 2021; Wall et al., 2021; Wang et al., 2021a). Most of these studies were based on  
84 the analysis of plasma samples collected from vaccinees following a short (3-4 weeks) interval  
85 between doses. Little is known about vaccine-elicited immune responses with longer dose  
86 intervals. Here, we characterized vaccine-elicited humoral responses in a cohort of SARS-CoV-2  
87 naïve and previously infected individuals that received the two doses with an extended interval of  
88 sixteen weeks.

89

90

## 91 RESULTS

92 We analyzed the longitudinal humoral responses after vaccination with the BNT162b2  
93 mRNA vaccine in blood samples, with an interval of around 16 weeks between the two doses  
94 (median [range]: 111 days [90–134 days]). The cohort included 22 SARS-CoV-2 naïve and 21  
95 previously infected (PI) donors tested SARS-CoV-2 positive by nasopharyngeal swab PCR  
96 around 9 months before their first dose (median [range]: 280 days [116–326 days]). In the cohort  
97 of PI individuals, 10 donors did not receive the second injection, leaving 11 PI donors with two  
98 doses. The blood samples were collected at different time points: prior the first dose of vaccine  
99 (V0), three weeks (V1, median [range]: 21 days [13–28 days]) and three months (V2, median  
100 [range]: 85 days [73–104 days]) after the first dose of vaccine and three weeks after the second  
101 vaccine injection (V3, median [range]: 21 days [13–42 days]). Data collected at V0 and V1 have  
102 been previously described (Tauzin et al., 2021). Basic demographic characteristics of the cohorts  
103 and detailed vaccination timepoints are summarized in Table 1 and Figure 1A.

104

### 105 Elicitation of SARS-CoV-2 antibodies against the full Spike and its receptor-binding 106 domain

107 To evaluate vaccine responses in SARS-CoV-2 naïve and PI individuals, we first  
108 measured the presence of SARS-CoV-2-specific antibodies (Abs) (IgG, IgM, IgA) recognizing the  
109 receptor-binding domain (Figure 1B-E) using an ELISA RBD assay or the native full-length S  
110 glycoprotein expressed at the cell surface (Figure 1F-I) using a cell-based ELISA assay. Both  
111 assays have been previously described (Anand et al., 2021; Beaudoin-Bussi eres et al., 2020;  
112 Pr evost et al., 2020). Prior to vaccination (V0), no SARS-CoV-2 specific Abs were detectable in  
113 SARS-CoV-2 naïve individuals, except for anti-Spike IgM (31.8% seropositivity) which are likely  
114 to be cross-reactive antibodies against the S2 subunit (Fraley et al., 2021; Hicks et al., 2020; Ng  
115 et al., 2020). SARS-CoV-2 PI individuals still had detectable Abs several months post-symptoms

116 onset, especially IgG, in agreement with previous observations (Anand et al., 2021; Dan et al.,  
117 2021; Tauzin et al., 2021; Wang et al., 2021b). For both groups, the first dose of vaccine induced  
118 a significant increase of total immunoglobulins (Igs) recognizing the RBD or the Spike protein  
119 three weeks post-vaccine (V1), with a significantly higher response for the PI group (Figure 1B-  
120 I). At V2 (i.e., 12 weeks post vaccination), while anti-Spike total Ig levels remained stable, we  
121 observed a decrease in anti-RBD total Ig levels in both groups, with the exception of some naïve  
122 donors where we observed an increase. We did not detect Abs recognizing the N protein for  
123 these donors (not shown), suggesting that they had not been infected between the two doses.  
124 This increase could therefore be linked to a delayed response or affinity maturation of the  
125 antibodies in the germinal center between V1 and V2. The second dose, which was administered  
126 ~16 weeks after the first one, strongly boosted the induction of anti-RBD Igs in the SARS-CoV-2  
127 naïve group, particularly IgG and IgA which reached higher levels, albeit not statistically  
128 significant, than those measured three weeks after the first dose (Figure 1D and E). For the PI  
129 group, the second dose also led to an increase in the level of total anti-RBD Igs that reached  
130 similar levels than after the first dose. Of note, the second dose in the naïve group elicited anti-  
131 RBD IgG levels that reached the same levels than in the PI group receiving two doses and  
132 significantly higher than PI receiving only one (Figure 1D). Similar patterns of responses were  
133 observed when we measured the level of Abs recognizing the full-length S glycoprotein (Figure  
134 1F-I).

135

### 136 **Recognition of SARS-CoV-2 Spike variants and other *Betacoronaviruses***

137 The BNT162b2 mRNA vaccine has been developed against the original Wuhan strain.  
138 However, SARS-CoV-2 is evolving, and many variants have emerged and spread rapidly  
139 worldwide. Some harbor specific mutations in S that are associated with increased transmissibility  
140 and/or immune evasion (Davies et al., 2020; Sabino et al., 2021; Tegally et al., 2020; Volz et al.,  
141 2021). Here, we evaluated the ability of Abs elicited by the Pfizer/BioNTech vaccine to recognize

142 different S proteins of VOCs (B.1.1.7, B.1.351, P.1 and B.1.612.2) and the VOI B.1.526 expressed  
143 at the cell surface of 293T cells by flow cytometry, using a method we have previously described  
144 (Figure 2, S1) (Gong et al., 2021; Prévost et al., 2020; Tausin et al., 2021).

145 As expected, none of the SARS-CoV-2 naïve plasma samples collected at V0 were able  
146 to recognize the SARS-CoV-2 S (D614G) or any of the variants tested here (B.1.1.7, B.1.351,  
147 B.1.617.2, P.1, B.1.526) (Figure 2A-F). In contrast, plasma from PI individuals recognized all  
148 tested SARS-CoV-2 variants at V0 (Figure 2A-F, S1). The first dose of vaccine strongly enhanced  
149 the recognition of the full D614G S and all the tested variants in both groups (Figure 2A-F). Three  
150 months after the first dose, the recognition slightly decreased but not significantly. As expected,  
151 the second dose strongly increased recognition of all VOC Spikes in the naïve group and reached  
152 levels that were significantly higher than after the first dose. In contrast, for the PI group, the  
153 second dose did not result in a better recognition than after the first dose. Of note, we observed  
154 no significant differences at V3 between PI individuals who received one or two doses, despite a  
155 shorter period since the last dose for PI individuals who received two doses. The recognition of  
156 all VOCs was slightly lower at V3 by the naïve group compared to the PI that received two doses  
157 (Figure 2A-F). When we compared Spike recognition between the SARS-CoV-2 variants, we  
158 observed that plasma from PI individuals before vaccination recognized less efficiently the  
159 different S variants compared to the D614G S, with the exception of B.1.1.7 S (Figure S1A). After  
160 the first and second dose, only B.1.351 and B.1.617.2 S were less efficiently recognized by  
161 plasmas from PI individuals (Figure S1B-D). For naïve individuals, even if the vaccination strongly  
162 increased the recognition of every VOC Spike tested, we observed that plasmas recognized the  
163 different SARS-CoV-2 variants less efficiently compared to D614G S except for the B.1.1.7 S  
164 (Figure S1).

165 We also evaluated whether vaccination elicited Abs that were able to recognize S  
166 glycoproteins from endemic human *Betacoronaviruses*, (HCoV-OC43 and HCoV-HKU1).

167 Interestingly, we observed that the first but not the second dose enhanced the recognition of  
168 HCoV-HKU1 S in the naïve group (Figure 2H). Moreover, we observed that plasma from PI donors  
169 better recognized HCoV-HKU1 S than plasma from naïve donors at every time point studied,  
170 suggesting that natural infection induced cross reactive Abs more efficiently than vaccination. In  
171 contrast, both doses did not significantly improve the recognition of HCoV-OC43 S (Figure 2G).

172 We then evaluated the capacity of the different plasma samples to bind S from highly  
173 pathogenic human coronaviruses (SARS-CoV-1 and MERS-CoV). We observed that PI  
174 individuals did not have Abs able to recognize MERS-CoV S before vaccination, in contrast to  
175 SARS-CoV-1 S (Figure 2I-J). This is likely related the closer genetic relationship between SARS-  
176 CoV-2 and SARS-CoV-1 than MERS-CoV (Rabaan et al., 2020; Sarkar et al., 2021). As  
177 previously observed (Tauzin et al., 2021), the first dose of vaccine significantly increased the  
178 recognition of the MERS-CoV S (Figure 2I) in both groups. However, the second dose did not  
179 enhance this recognition. On the other hand, both vaccine doses significantly increased the level  
180 of recognition of the SARS-CoV-1 Spike in the naïve group (Figure 2J). In the PI group, only the  
181 first dose significantly improved the recognition. We note that the long interval between doses  
182 brings SARS-CoV-2 naïve individuals to recognize the different variant Spikes and related HCoV  
183 to the same extent than previously-infected individuals.

184

### 185 **Functional activities of vaccine-elicited antibodies**

186 We (Tauzin et al., 2021) and others (Collier et al., 2021; Goel et al., 2021b; Planas et al.,  
187 2021b; Sahin et al., 2020) reported that three weeks post first Pfizer/BioNTech dose, SARS-CoV-  
188 2 S specific antibodies with weak neutralizing properties are elicited. Nevertheless, these Abs  
189 present robust Fc-mediated effector functions as measured by their capacity to mediate antibody-  
190 dependent cellular cytotoxicity (ADCC) (Tauzin et al., 2021). To obtain a better understanding of  
191 this functional property over time, we tested all plasma samples with our previously reported



192 ADCC assay (Anand et al., 2021; Beaudoin-Bussieres et al., 2021; Tauzin et al., 2021; Ullah et  
193 al., 2021). As expected, and in agreement with the absence of SARS-CoV-2 S specific antibodies  
194 at baseline, no ADCC activity was observed for the naïve group before vaccination (Figure 3A).  
195 Plasma from the PI group maintained some levels of ADCC activity before vaccination, in  
196 agreement with a longitudinal study following immune responses in convalescent donors (Anand  
197 et al., 2021). Three weeks after the first dose, ADCC activity was elicited in both groups, but  
198 significantly higher in the PI group. A decline in ADCC responses was observed in both groups  
199 nine weeks after V1 (V2, i.e., 12 weeks post vaccination). The second dose strongly boosted  
200 ADCC activity in the naïve group but remained stable for the PI groups. We noted that the levels  
201 of ADCC activity were significantly higher in the PI group at all timepoints (Figure 3A).

202 Neutralizing activity in plasma is thought to play an important role in vaccine efficacy  
203 (Jackson et al., 2020; Muruato et al., 2020; Polack et al., 2020). Accordingly, it has been recently  
204 identified as an immune-correlate of protection in the mRNA-1273 COVID-19 vaccine efficacy trial  
205 (Gilbert et al., 2021). To evaluate the vaccine neutralizing response over time, we measured the  
206 capacity of plasma samples to neutralize pseudoviral particles carrying the SARS-CoV-2 S  
207 D614G glycoprotein (Figure 3B). We did not detect a significant increase in neutralization in  
208 plasma isolated three weeks post vaccination of the naïve group, as previously described (Tauzin  
209 et al., 2021). Interestingly, nine weeks later (V2, i.e., 12 weeks post vaccination), we observed  
210 increased neutralizing activity in a few donors (Figure 3B). All donors presented a significant  
211 increase in neutralizing activity three weeks after the second dose. Importantly, the level of  
212 neutralizing activity of double vaccinated naïve individuals reached the same levels than in the PI  
213 group after one or two doses. In this latter group (PI), we measured low neutralizing activity before  
214 vaccination, consistent with remaining neutralizing activity in convalescent donors after several  
215 months post symptoms onset (Anand et al., 2021; Gaebler et al., 2021; Tauzin et al., 2021). As  
216 previously described, the first dose strongly increased neutralization activity (Stamatatos et al.,  
217 2021; Tauzin et al., 2021), but this activity significantly decreased a few weeks after (V2, i.e., 12

218 weeks post vaccination). The second dose boosted the neutralizing activity to the levels reached  
219 three weeks after the first dose. No difference in neutralization was observed between V1 and V3  
220 for PI individuals. In contrast, in naïve individuals we observed a significantly higher neutralizing  
221 activity after the second dose compared to the first one (Figure 3B). Thus, while one dose is  
222 required to reach maximum neutralization activity in PI individuals, this activity decays over time  
223 and a second dose is required to bring back its maximum potential. On the other hand, naïve  
224 individuals requires both doses to achieve the same level of PI vaccinated individuals.

225

### 226 **Neutralizing activity against variants of concern**

227 SARS-CoV-2 is evolving, and variants of concern are emerging globally (Davies et al.,  
228 2020; Prévost and Finzi, 2021; Sabino et al., 2021; Tegally et al., 2020; Volz et al., 2021). To  
229 evaluate whether the long interval between the two doses impacted the capacity of vaccine-  
230 elicited antibodies to neutralize VOCs and VOI, we measured the neutralizing activity against  
231 pseudoviral particles bearing selected variant Spikes (Figure 4, S2). For all the variants tested,  
232 we observed a similar pattern than for the D614G S, with neutralizing Abs mainly induced after  
233 the second dose in the naïve group (Figure 4A-E). Previously-infected individuals followed a  
234 different pattern. While their plasma had some levels of neutralizing activity at baseline, it gained  
235 potency and breadth after the first dose. A second dose did not further enhance this activity.  
236 Accordingly, we found no significant differences in neutralizing activity in plasma from PIs that  
237 received one or two doses measured at V3 (i.e., week 19).

238 We also noted that, with the exception of B.1.1.7, plasma from the PI group prior to  
239 vaccination (V0) neutralized less efficiently all pseudoviral particles bearing variant Spikes  
240 compared to the D614G (Figure S2A). Importantly, both doses boosted the neutralizing activity  
241 against all variants and SARS-CoV-1 Spike at V3 (Figure S2D).

242 Vaccination of PI individuals was shown to increase neutralization against pseudoviral  
243 particles bearing the SARS-CoV-1 Spike (Stamatatos et al., 2021; Tauzin et al., 2021). This Spike  
244 is used as a representative variant that is even more dissimilar to the vaccine, which was based  
245 on the ancestral Wuhan strain. While only one dose was sufficient to provide SARS-CoV-1  
246 neutralizing capacity in PI individuals, two were required in naïve individuals. Remarkably, plasma  
247 from naïve individuals reached the same level of neutralizing activity against pseudoviral particles  
248 bearing the SARS-CoV-1 Spike than PI. Thus, suggesting that the delayed boosting in naïve  
249 individuals allows antibody maturation resulting in enhanced breadth (Figure 4F).

250

### 251 **Humoral responses in individuals receiving a short dose interval regimen**

252 We also analyzed the humoral responses of 11 SARS-CoV-2 naïve donors from a  
253 separate cohort who received their two doses of Pfizer/BioNTech mRNA vaccine three weeks  
254 apart (median [range]: 21 days [21–21 days]) (Table 1 and Figure 5A). Unfortunately, for these  
255 donors, blood samples were only collected at baseline (V0, prior to vaccination) and 22 weeks  
256 (median [range]: 152 days [147–158 days]) after the first dose, thus precluding a direct side-by-  
257 side comparison of humoral responses with our cohort of naïve individuals that received the two  
258 doses 16 weeks apart. In other words, the V3 of individuals receiving the second dose following  
259 a short interval regimen was collected ~19 weeks post boost whereas the V3 of those with a long  
260 interval corresponds to 3 weeks post boost (Figure 1A and 5A). While not a perfect match, we  
261 decided to compare the humoral responses of short interval vaccinated individuals with those  
262 from PI that received a single dose since their V3 was collected ~19 weeks post vaccination.  
263 While we observed no significant differences in total Ig recognizing the RBD or the full S (Figure  
264 5B and F), single dose PI individuals had more anti-RBD IgG and IgA than naïve donors who  
265 received their two doses 3 weeks apart (Figure 5D and E). Despite minor differences in the overall  
266 amount of anti-RBD or anti-Spike Abs, we observed major differences related to their capacity to  
267 recognize the full Spike. Plasma from short interval vaccinated individuals was significantly less

268 efficient at recognizing the D614G S and all other S variants tested (Figure 5J). Major differences  
269 were also observed, particularly related to their capacity to mediate ADCC (Figure 5K) or  
270 neutralize pseudoviral particles bearing D614G or any of the variant Spike tested (Figure 5L).  
271 Indeed, the naïve donors with a short interval between doses had a very low ID<sub>50</sub> against all the  
272 variant tested ~19 weeks after the vaccine series. No neutralizing activity against SARS-CoV-1  
273 was observed (Figure 5L). In contrast, plasmas from PI individual who received just one dose  
274 presented neutralizing activity against all the SARS-CoV-2 variants but also the SARS-CoV-1  
275 pseudoviruses (Figure 5L).

276

277

## 278 **Integrated analysis of vaccine responses elicited with a sixteen-weeks interval between** 279 **doses**

280 When studying the network of pairwise correlations among all studied immune variables  
281 in SARS-CoV-2 naïve individuals (Figure 6), we observed a sparsely interconnected network after  
282 the first vaccine dose with focused clusters among binding and neutralization responses,  
283 respectively. Over time, the network induced upon 1<sup>st</sup> vaccination slightly collapsed until the  
284 delayed 2<sup>nd</sup> vaccination triggered a dense network of positive correlations involving binding  
285 neutralization responses against several SARS-CoV-2 variants and SARS-CoV-1 (but hardly  
286 OC43, HKU1, or MERS spike), ADCC, and memory B cell responses.

287

288

289

## 290 **DISCUSSION**

291           The approved regimen of the BNT162b2 mRNA vaccine is the administration of two doses  
292 within a short interval of 3-4 weeks. Despite the rapid approval of different vaccine platforms,  
293 generating the required doses to immunize the world population represents a daunting task  
294 (Moore and Klasse, 2020). Confronted to vaccine scarcity, some jurisdictions decided to increase  
295 the interval between doses in order to increase the number of immunized individuals. This  
296 decision led to concerns about vaccine efficacy, notably against emergent variants rapidly  
297 spreading worldwide and more resistant notably against neutralizing Abs induced by vaccination  
298 (Annavajhala et al., 2021a; Planas et al., 2021a; Puranik et al., 2021; Wall et al., 2021; Wang et  
299 al., 2021a). Here, we measured the humoral responses of SARS-CoV-2 naïve and SARS-CoV-2  
300 PI individuals who received their two doses sixteen weeks apart.

301           We observed that in the SARS-CoV-2 naïve group the BNT162b2 mRNA vaccine elicited  
302 antibodies with weak neutralizing activity but strong Fc-mediated functions three weeks after the  
303 first dose (Tauzin et al., 2021). These responses declined in the following weeks in the absence  
304 of a boost. However, administration of the second dose sixteen weeks later strongly enhanced  
305 these responses, notably neutralization against some VOCs/VOIs and even the divergent SARS-  
306 CoV-1. Therefore, despite initial concerns, the long interval between the doses did not result in  
307 poor immune responses, in agreement with recent findings (Parry et al., 2021). The idea behind  
308 the strategy of delaying the second dose was to provide some level of immunity to a larger number  
309 of individuals than if the second dose would have been saved to administer them three weeks  
310 later. However, despite the immunological benefits of increasing the interval between the two  
311 doses, this also increases the probability of being infected before the boost.

312           Several studies have shown that vaccination of previously-infected individuals elicits  
313 strong cellular and humoral responses (Efrati et al., 2021; Lozano-Ojalvo et al., 2021; Stamatatos  
314 et al., 2021; Tauzin et al., 2021; Urbanowicz et al., 2021). In agreement with these studies, we

315 found that vaccination of these individuals resulted in the induction of strong humoral responses.  
316 These responses remained relatively stable over time. We noticed that the second dose did not  
317 result in a significant enhancement of these responses, even with a long interval of 16 weeks  
318 between doses. Our results demonstrate that, while the second dose boosts the humoral  
319 response, PI individuals reach their peak of immunity after the first dose. Altogether, these results  
320 suggest that a second dose for PI individuals might be delayed beyond sixteen weeks after the  
321 first dose. These observations are in agreement with recent studies showing that PI individuals  
322 had maximal humoral and CD4+ and CD8+ T cell responses after the first dose of an mRNA  
323 vaccine; the second did not strongly boost these responses (Goel et al., 2021a; Lozano-Ojalvo et  
324 al., 2021; Painter et al., 2021).

325 In contrast, here we show that a delayed second vaccine boost in naïve individuals  
326 significantly enhances several immune responses and tightens the network of linear correlations  
327 among those. The involved immune variables were humoral and cellular responses directed  
328 against SARS-CoV-2, including diverse variants, and SARS-CoV-1, but not or marginally against  
329 OC43, HKU1, or MERS. Thus, the potency, quality, and concerted triggering of immune  
330 responses appear enhanced in naïve individuals vaccinated with a prolonged interval of 16 weeks  
331 between first and second shot, comparable to those obtained after vaccination of previously  
332 infected individuals.

333

334 We also analyzed humoral responses in a cohort of naïve donors who received their two  
335 doses according to the approved three-week interval. Plasma collected ~19 weeks post second  
336 dose, had poor humoral activities with low neutralizing activity against D614G strain and even  
337 weaker activity against some VOCs/VOIs including B.1.617.2. These results are in agreement  
338 with recent studies showing that circulating antibody levels and neutralizing activity decline over

339 time (Doria-Rose et al., 2021; Goel et al., 2021a). In contrast, we observed that PI individuals who  
340 received one dose had better responses 19 weeks after their dose.

341

342 Field effectiveness studies in Israel and the USA, where a short interval between doses is  
343 recommended, suggest waning protection of the BNT162b2 mRNA vaccine series against non-  
344 severe disease after a period of approximately 5 months (CDC, 2021; Goldberg et al., 2021; JCVI,  
345 2021; Tartof et al., 2021). However, SARS-CoV-2 specific memory B cell and CD4+ T cell  
346 responses remains stable for the following 6 months, likely protecting from severe disease (Goel  
347 et al., 2021a). Whether the same kind of waning will be observed with an extended schedule  
348 remains to be evaluated. It will be of critical importance to monitor immune responses and vaccine  
349 effectiveness of these extended schedules over time. If the strong humoral response seen with  
350 this extended schedule is longer-lasting than immune responses following the authorized  
351 schedule, the need of a third dose might be delayed and this could have significant implications  
352 regarding control of COVID-19.

353

354 To end this pandemic, it will be necessary to rapidly vaccinate the world's population,  
355 including in countries where vaccines are poorly available. The research community around the  
356 globe rapidly generated a wealth of data related to vaccine-elicited immune responses and  
357 vaccine efficacy. Globally, these results suggest that the current vaccine strategy that was initially  
358 deployed could be improved. Our results suggest that modifying the interval at which the two  
359 doses are administered might be an important factor to take into account. It will be important to  
360 keep in mind that a fine balance needs to be achieved in order to avoid infection between the two  
361 doses and at the same time provide sufficient time to elicit optimal humoral responses.

362

363

## 364 **ACKNOWLEDGMENTS**

365           The authors are grateful to the donors who participated in this study. The authors thank  
366 the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. We thank Dr. Stefan  
367 Pöhlmann (Georg-August University, Germany) for the plasmid coding for SARS-CoV-2 and  
368 SARS-CoV-1 S glycoproteins and Dr. M. Gordon Joyce (U.S. MHRP) for the monoclonal antibody  
369 CR3022. This work was supported by le Ministère de l'Économie et de l'Innovation du Québec,  
370 Programme de soutien aux organismes de recherche et d'innovation to A.F. and by the Fondation  
371 du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR  
372 operating Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2  
373 for SARS-CoV-2 Variant Research to A.F., and by an Exceptional Fund COVID-19 from the  
374 Canada Foundation for Innovation (CFI) #41027 to A.F. and D.E.K. Work on variants presented  
375 was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration  
376 with Fonds de Recherche du Québec Santé (FRQS) to A.F. This work was also partially supported  
377 by a CIHR COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2  
378 Variant Research to MC. A.F. is the recipient of Canada Research Chair on Retroviral Entry no.  
379 RCHS0235 950-232424. MC is a Tier II Canada Research Chair in Molecular Virology and  
380 Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS  
381 Merit Research Scholar. G.B.B. is the recipient of a FRQS PhD fellowship and J.P. is the recipient  
382 of a CIHR PhD fellowship. G.S. is supported by a scholarship from the Department of  
383 Microbiologie, Infectiologie et Immunology of Université de Montréal. R.G. and A.L. were  
384 supported by MITACS Accélération postdoctoral fellowships. The funders had no role in study  
385 design, data collection and analysis, decision to publish, or preparation of the manuscript. We  
386 declare no competing interests.

387

388



389 **AUTHOR CONTRIBUTIONS**

390 A.T. and A.F. conceived the study. A.T., G.B.B., R.G., J.Prévost, M.N., J.R., D.E.K., and  
391 A.F. designed experimental approaches. A.T., S.Y.G., G.B.B., D.V., R.G., L.N., L.M., M.Benlarbi,  
392 D.C., M.N., A.L., J.Prévost, M.Boutin, G.S., A.N., C.B., Y.B., M.D., D.E.K., and A.F. performed,  
393 analyzed, and interpreted the experiments. A.T. and R.D. performed statistical analysis. S.Y.G.,  
394 G.B.B., A.L., J.Prévost, G.G.L., H.M., G.G., Y.B., J.R., M.C and A.F. contributed unique reagents.  
395 J.Perreault, L.G., C.M., P.A., R.B., R.R., G.C.M., C.T. and V.M.-L. collected and provided clinical  
396 samples. G.D.S., and N.B. provided scientific input related to VOC and vaccine efficacy. A.T., and  
397 A.F. wrote the manuscript with inputs from others. Every author has read, edited, and approved  
398 the final manuscript.

399

400 **DECLARATION OF INTERESTS**

401 The authors declare no competing interests.

402

403 **FIGURE LEGENDS**

404 **Figure 1. Elicitation of RBD- and Spike-specific antibodies in SARS-CoV-2 naïve and**  
405 **previously-infected individuals.**

406 (A) SARS-CoV-2 vaccine cohort design. (B-E) Indirect ELISA was performed by incubating  
407 plasma samples from naïve and PI donors collected at V0, V1, V2 and V3 with recombinant  
408 SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated (B) anti-  
409 human IgM+IgG+IgA (C) anti-human IgM, (D) anti-human IgG, or (E) anti-human IgA. Relative  
410 light unit (RLU) values obtained with BSA (negative control) were subtracted and further  
411 normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. (F-I) Cell-  
412 based ELISA was performed by incubating plasma samples from naïve and PI donors collected  
413 at V0, V1, V2 and V3 with HOS cells expressing full-length SARS-CoV-2 S. Anti-S Ab binding  
414 was detected using HRP-conjugated (F) anti-human IgM+IgG+IgA (G) anti-human IgM, (H) anti-  
415 human IgG, or (I) anti-human IgA. RLU values obtained with parental HOS (negative control) were  
416 subtracted and further normalized to the signal obtained with the CR3022 mAb present in each  
417 plate. Naïve and PI donors with a long interval between the two doses are represented by red  
418 and black points respectively and PI donors who received just one dose by blue points. (Left  
419 panels) Each curve represents the normalized RLUs obtained with the plasma of one donor at  
420 every time point. Mean of each group is represented by a bold line. The time of vaccine dose  
421 injections is indicated by black triangles. (Right panels) Plasma samples were grouped in  
422 different time points (V0, V1, V2 and V3). Undetectable measures are represented as white  
423 symbols, and limits of detection are plotted. Error bars indicate means  $\pm$  SEM. (\* P < 0.05; \*\* P <  
424 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001; ns, non-significant).

425

426 **Figure 2. Binding of vaccine-elicited antibodies to SARS-CoV-2 Spike variants and other**  
427 ***Betacoronaviruses*.**

428 293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants  
429 and other human *Betacoronavirus* Spike and stained with the CV3-25 Ab or with plasma from  
430 naïve or PI donors collected at V0, V1, V2 and V3 and analyzed by flow cytometry. The values  
431 represent the median fluorescence intensities (MFI) (**G,H** and **I**) or the MFI normalized by CV3-  
432 25 Ab binding (**A-F, J**). Naïve and PI donors with a long interval between the two doses are  
433 represented by red and black points respectively and PI donors who received just one dose by  
434 blue points. (**Left panels**) Each curve represents the MFI or the normalized MFIs obtained with  
435 the plasma of one donor at every time point. Mean of each group is represented by a bold line.  
436 The time of vaccine dose injections is indicated by black triangles. (**Right panels**) Plasma  
437 samples were grouped in different time points (V0, V1, V2 and V3). Undetectable measures are  
438 represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$   
439 SEM. (\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ ; \*\*\*\*  $P < 0.0001$ ; ns, non-significant).

440

441 **Figure 3. Fc-effector function and neutralization activities in SARS-CoV-2 naïve and**  
442 **previously-infected individuals before and after Pfizer/BioNTech mRNA vaccine.**

443 (**A**) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-Spike cells and were used  
444 as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based  
445 ADCC assay. (**B**) Neutralizing activity was measured by incubating pseudoviruses bearing SARS-  
446 CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2  
447 cells. Neutralization half maximal inhibitory serum dilution ( $ID_{50}$ ) values were determined using a  
448 normalized non-linear regression using GraphPad Prism software. Naïve and PI donors with a  
449 long interval between the two doses are represented by red and black points respectively and PI

450 donors who received just one dose by blue points. **(Left panels)** Each curve represents the values  
451 obtained with the plasma of one donor at every time point. Mean of each group is represented by  
452 a bold line. The time of vaccine dose injections is indicated by black triangles. **(Right panels)**  
453 Plasma samples were grouped in different time points (V0, V1, V2 and V3). Undetectable  
454 measures are represented as white symbols, and limits of detection are plotted. Error bars  
455 indicate means  $\pm$  SEM. (\* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001; ns, non-significant).

456

457 **Figure 4. Neutralization activities against different SARS-CoV-2 VOCs and SARS-CoV-1 in**  
458 **naïve and previously-infected individuals before and after Pfizer/BioNTech mRNA vaccine.**

459 Neutralizing activity was measured by incubating pseudoviruses bearing the indicated SARS-  
460 CoV-2 VOCs or SARS-CoV-1 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C  
461 before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>)  
462 values were determined using a normalized non-linear regression using GraphPad Prism  
463 software. Naïve and PI donors with a long interval between the two doses are represented by red  
464 and black points respectively and PI donors who received just one dose by blue points. **(Left**  
465 **panels)** Each curve represents the values obtained with the plasma of one donor at every time  
466 point. Mean of each group is represented by a bold line. The time of vaccine dose injections is  
467 indicated by black triangles. **(Right panels)** Plasma samples were grouped in different time points  
468 (V0, V1, V2 and V3). Undetectable measures are represented as white symbols, and limits of  
469 detection are plotted. Error bars indicate means  $\pm$  SEM. (\* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001;  
470 \*\*\*\* P < 0.0001; ns, non-significant).

471

472 **Figure 5. Humoral responses in SARS-CoV-2 naïve individuals that received a short dose**  
473 **interval versus previously-infected individuals receiving only one dose.**

474 (A) SARS-CoV-2 vaccine cohort design. (B-E) Indirect ELISA was performed by incubating  
475 plasma samples from naïve and PI donors collected at V3 with recombinant SARS-CoV-2 RBD  
476 protein. Anti-RBD Ab binding was detected using HRP-conjugated (B) anti-human IgM+IgG+IgA  
477 (C) anti-human IgM, (D) anti-human IgG, or (E) anti-human IgA. Relative light unit (RLU) values  
478 obtained with BSA (negative control) were subtracted and further normalized to the signal  
479 obtained with the anti-RBD CR3022 mAb present in each plate. (F-I) Cell-based ELISA was  
480 performed by incubating plasma samples from naïve and PI donors collected at V3 with HOS  
481 cells expressing full-length SARS-CoV-2 S. Anti-S Ab binding was detected using HRP-  
482 conjugated (F) anti-human IgM+IgG+IgA (G) anti-human IgM, (H) anti-human IgG, or (I) anti-  
483 human IgA. RLU values obtained with parental HOS (negative control) were subtracted and  
484 further normalized to the signal obtained with the CR3022 mAb present in each plate. (J) 293T  
485 cells were transfected with the indicated full-length S and stained with the CV3-25 Ab or with  
486 plasma from naïve or PI donors collected at V3 and analyzed by flow cytometry. The values  
487 represent the MFI normalized by CV3-25 Ab binding. (K) CEM.NKr parental cells were mixed at  
488 a 1:1 ratio with CEM.NKr-Spike cells and were used as target cells. PBMCs from uninfected  
489 donors were used as effector cells in a FACS-based ADCC assay. (L) Neutralizing activity was  
490 measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins or SARS-CoV-1 S  
491 glycoprotein, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells.  
492 Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were determined using a  
493 normalized non-linear regression using GraphPad Prism software. PI donors who received one  
494 dose are represented by blue points and naïve donors with a short interval between the two doses  
495 by green points. Plasma samples were grouped at V3. Undetectable measures are represented  
496 as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (\* P <  
497 0.05; \*\* P < 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001; ns, non-significant).

498

499 **Figure 6. Mesh correlations of humoral response parameters in SARS-CoV-2 naïve**  
500 **individuals before and after Pfizer/BioNTech mRNA vaccine.**

501 Edge bundling correlation plots where red and blue edges represent positive and negative  
502 correlations between connected parameters, respectively. Only significant correlations ( $p < 0.05$ ,  
503 Spearman rank test) are displayed. Nodes are color coded based on the grouping of parameters  
504 according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge  
505 bundling plots are shown for correlation analyses using four different datasets; i.e., SARS-CoV-2  
506 naïve individuals at V0, V1, V2 and V3 respectively.

507

508

509

**Table 1. Characteristics of the vaccinated SARS-CoV-2 cohorts**

		SARS-CoV-2 Naïve		SARS-CoV-2 Previously infected		
		Two doses Short interval (n=11)	Two doses Long interval (n=22)	Two doses Long interval (n=11)	One dose (n=10)	Entire cohort (n=21)
Age		40 (30-52)	51 (21-59)	44 (39-65)	56 (23-65)	47 (23-65)
Gender	Male (n)	3	7	7	2	9
	Female (n)	8	15	4	8	12
Days between symptom onset and the 1 <sup>st</sup> dose <sup>a</sup>		N/A	N/A	274 (185-321)	280 (116-326)	280 (116-326)
Days between the 1 <sup>st</sup> and 2 <sup>nd</sup> dose <sup>a</sup>		21 (21-21)	112 (108-120)	111 (90-134)	N/A	N/A
Days between V0 and the 1 <sup>st</sup> dose <sup>a</sup>		0 (0-7)	2 (0-49)	23 (0-95)	13 (1-73)	17 (1-95)
Days between the 1 <sup>st</sup> dose and V1 <sup>a</sup>		N/A	21 (16-28)	20 (17-25)	20 (13-21)	20 (13-25)
Days between the 1 <sup>st</sup> dose and V2 <sup>a</sup>		N/A	83 (73-92)	89 (83-97)	90 (84-104)	90 (83-104)
Days between V2 and the 2 <sup>nd</sup> dose <sup>a</sup>		N/A	28 (21-38)	23 (2-42)	N/A	N/A
Days between the 1 <sup>st</sup> dose and V3 <sup>a</sup>		152 (147-158)	134 (123-144)	138 (103-152)	134 (120-146)	137 (103-152)
Days between the 2 <sup>nd</sup> dose and V3 <sup>a</sup>		131 (126-137)	21 (14-34)	21 (13-42)	N/A	N/A

510

511 <sup>a</sup> Values displayed are medians, with ranges in parentheses.

512 **STAR METHODS**

513

514 **RESOURCE AVAILABILITY**

515

516 **Lead contact**

517 Further information and requests for resources and reagents should be directed to and will be

518 fulfilled by the lead contact, Andrés Finzi ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca))

519

520 **Materials availability**

521 All unique reagents generated during this study are available from the Lead contact without  
522 restriction.

523

524 **Data and code availability**

525 The published article includes all datasets generated and analyzed for this study. Further  
526 information and requests for resources and reagents should be directed to and will be fulfilled by  
527 the Lead Contact Author ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)).

528

529 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

530

531 **Ethics Statement**

532 All work was conducted in accordance with the Declaration of Helsinki in terms of informed  
533 consent and approval by an appropriate institutional board. Blood samples were obtained from  
534 donors who consented to participate in this research project at Centre Hospitalier de l'Université  
535 de Montréal (CHUM) and at Azienda Socio-Sanitaria Territoriale (ASST) Santi Paolo e Carlo,  
536 Milan. The study was approved by the respective Institutional Review Boards (no. 19.381 at  
537 CHUM and no. 2020/ST/049 at ASST Santi Paolo et Carlo). Plasma and PBMCs were isolated



538 by centrifugation and Ficoll gradient, and samples stored at -80°C and in liquid nitrogen,  
539 respectively, until use.

540

#### 541 **Human subjects**

542 No specific criteria such as number of patients (sample size), clinical or demographic were used  
543 for inclusion, beyond PCR confirmed SARS-CoV-2 infection in adults.

544

#### 545 **Plasma and antibodies**

546 Plasma from SARS-CoV-2 naïve and PI donors were collected, heat-inactivated for 1 hour at  
547 56°C and stored at -80°C until ready to use in subsequent experiments. Plasma from uninfected  
548 donors collected before the pandemic were used as negative controls and used to calculate the  
549 seropositivity threshold in our ELISA, cell-based ELISA, ADCC and flow cytometry assays (see  
550 below). The RBD-specific monoclonal antibody CR3022 was used as a positive control in our  
551 ELISA, cell-based ELISA, and flow cytometry assays and was previously described (Anand et al.,  
552 2020; Beaudoin-Bussi eres et al., 2020; Meulen et al., 2006; Pr evost et al., 2020). Horseradish  
553 peroxidase (HRP)-conjugated Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA;  
554 Jackson ImmunoResearch Laboratories) or specific for the Fc region of human IgG (Invitrogen),  
555 the Fc region of human IgM (Jackson ImmunoResearch Laboratories) or the Fc region of human  
556 IgA (Jackson ImmunoResearch Laboratories) were used as secondary Abs to detect Ab binding  
557 in ELISA and cell-based ELISA experiments. Alexa Fluor-647-conjugated goat anti-human Abs  
558 able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson ImmunoResearch Laboratories)  
559 were used as secondary Ab to detect plasma binding in flow cytometry experiments.

560

#### 561 **Cell lines**

562 293T human embryonic kidney and HOS cells (obtained from ATCC) were maintained at 37°C  
563 under 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal  
564 bovine serum (FBS) (VWR) and 100 µg/ml of penicillin-streptomycin (Wisent). CEM.NKr CCR5+  
565 cells (NIH AIDS reagent program) were maintained at 37°C under 5% CO<sub>2</sub> in Roswell Park  
566 Memorial Institute (RPMI) 1640 medium (Gibco) containing 10% FBS and 100 µg/ml of penicillin-  
567 streptomycin. 293T-ACE2 cell line was previously reported (Prévost et al., 2020). HOS and  
568 CEM.NKr CCR5+ cells stably expressing the SARS-CoV-2 S glycoproteins were previously  
569 reported (Anand et al., 2021).

570

## 571 **METHOD DETAILS**

### 572 **Plasmids**

573 The plasmids expressing the human coronavirus Spike glycoproteins of SARS-CoV-2, SARS-  
574 CoV-1 (Hoffmann et al., 2013, 2020), HCoV-OC43 (Prévost et al., 2020) and MERS-CoV (Park  
575 et al., 2016) were previously reported. The HCoV-HKU1 S expressing plasmid was purchased  
576 from Sino Biological. The plasmids encoding the different SARS-CoV-2 Spike variants (D614G,  
577 B.1.1.7, B.1.351, P.1, B.1.526 and B.1.617.2) were previously described (Beaudoin-Bussièrès et  
578 al., 2020; Gong et al., 2021; Li et al., 2021; Tausin et al., 2021).

579

### 580 **Protein expression and purification**

581 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density  
582 of 1 x 10<sup>6</sup> cells/mL at 37°C with 8 % CO<sub>2</sub> with regular agitation (150 rpm). Cells were transfected  
583 with a plasmid coding for SARS-CoV-2 S RBD (Beaudoin-Bussièrès et al., 2020) using  
584 ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week  
585 later, cells were pelleted and discarded. Supernatants were filtered using a 0.22 µm filter (Thermo  
586 Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as  
587 directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against

588 phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess  
589 purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.

590

591

592

### 593 **Enzyme-Linked Immunosorbent Assay (ELISA)**

594 The SARS-CoV-2 RBD ELISA assay used was previously described (Beaudoin-Bussi eres et al.,  
595 2020; Pr evost et al., 2020). Briefly, recombinant SARS-CoV-2 S RBD proteins (2.5 µg/ml), or  
596 bovine serum albumin (BSA) (2.5 µg/ml) as a negative control, were prepared in PBS and were  
597 adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked  
598 with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween20 and 2% BSA) for 1h at  
599 room temperature. Wells were then washed four times with washing buffer (Tris-buffered saline  
600 [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/ml) or a 1/250 dilution of plasma were  
601 prepared in a diluted solution of blocking buffer (0.1 % BSA) and incubated with the RBD-coated  
602 wells for 90 minutes at room temperature. Plates were washed four times with washing buffer  
603 followed by incubation with secondary Abs (diluted in a diluted solution of blocking buffer (0.4%  
604 BSA)) for 1h at room temperature, followed by four washes. HRP enzyme activity was determined  
605 after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer  
606 Life Sciences). Light emission was measured with a LB942 TriStar luminometer (Berthold  
607 Technologies). Signal obtained with BSA was subtracted for each plasma and was then  
608 normalized to the signal obtained with CR3022 present in each plate. The seropositivity threshold  
609 was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative  
610 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

611

### 612 **Cell-Based ELISA**

613 Detection of the trimeric SARS-CoV-2 S at the surface of HOS cells was performed by a  
614 previously-described cell-based enzyme-linked immunosorbent assay (ELISA) (Anand et al.,  
615 2021). Briefly, parental HOS cells or HOS-Spike cells were seeded in 96-well plates ( $4 \times 10^4$  cells  
616 per well) overnight. Cells were blocked with blocking buffer (10 mg/ml nonfat dry milk, 1.8 mM  
617  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 25 mM Tris [pH 7.5], and 140 mM NaCl) for 30 min. CR3022 mAb (1  $\mu\text{g/ml}$ )  
618 or plasma (at a dilution of 1/250) were prepared in blocking buffer and incubated with the cells for  
619 1h at room temperature. Respective HRP-conjugated Abs were then incubated with the samples  
620 for 45 min at room temperature. For all conditions, cells were washed 6 times with blocking buffer  
621 and 6 times with washing buffer (1.8 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 25 mM Tris [pH 7.5], and 140 mM  
622 NaCl). HRP enzyme activity was determined after the addition of a 1:1 mix of Western Lightning  
623 oxidizing and luminol reagents (PerkinElmer Life Sciences). Light emission was measured with  
624 an LB942 TriStar luminometer (Berthold Technologies). Signal obtained with parental HOS was  
625 subtracted for each plasma and was then normalized to the signal obtained with CR3022 mAb  
626 present in each plate. The seropositivity threshold was established using the following formula:  
627 mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-  
628 pandemic SARS-CoV-2 negative plasma).

629

### 630 **Cell surface staining and flow cytometry analysis**

631 293T cells were co-transfected with a GFP expressor (pIRES2-GFP, Clontech) in combination  
632 with plasmids encoding the full-length Spikes of SARS-CoV-2 variants or Spikes from different  
633 *Betacoronaviruses*. 48h post-transfection, S-expressing cells were stained with the CV3-25 Ab  
634 (Jennewein et al., 2021) or plasma (1/250 dilution). AlexaFluor-647-conjugated goat anti-human  
635 IgM+IgG+IgA Abs (1/800 dilution) were used as secondary Abs. The percentage of transfected  
636 cells (GFP+ cells) was determined by gating the living cell population based on viability dye  
637 staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSRII cytometer (BD Biosciences)  
638 and data analysis was performed using FlowJo v10.7.1 (Tree Star). The seropositivity threshold

639 was established using the following formula: (mean of pre-pandemic SARS-CoV-2 negative  
640 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma). The  
641 conformational-independent S2-targeting mAb CV3-25 was used to normalize Spike expression.  
642 CV3-25 was shown to effectively recognize all SARS-CoV-2 Spike variants (Li et al., 2021).

643

#### 644 **ADCC assay**

645 This assay was previously described (Anand et al., 2021). For evaluation of anti-SARS-CoV-2  
646 antibody-dependent cellular cytotoxicity (ADCC), parental CEM.NKr CCR5+ cells were mixed at  
647 a 1:1 ratio with CEM.NKr cells stably expressing a GFP-tagged full length SARS-CoV-2 Spike  
648 (CEM.NKr.SARS-CoV-2.Spike cells). These cells were stained for viability (AquaVivid; Thermo  
649 Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell proliferation dye eFluor670; Thermo  
650 Fisher Scientific) to be used as target cells. Overnight rested PBMCs were stained with another  
651 cellular marker (cell proliferation dye eFluor450; Thermo Fisher Scientific) and used as effector  
652 cells. Stained target and effector cells were mixed at a ratio of 1:10 in 96-well V-bottom plates.  
653 Plasma (1/500 dilution) or monoclonal antibody CR3022 (1 µg/mL) were added to the appropriate  
654 wells. The plates were subsequently centrifuged for 1 min at 300g, and incubated at 37°C, 5%  
655 CO<sub>2</sub> for 5 hours before being fixed in a 2% PBS-formaldehyde solution. ADCC activity was  
656 calculated using the formula:  $[(\% \text{ of GFP+ cells in Targets plus Effectors}) - (\% \text{ of GFP+ cells in}$   
657  $\text{Targets plus Effectors plus plasma/antibody})]/(\% \text{ of GFP+ cells in Targets}) \times 100$  by gating on  
658 transduced live target cells. All samples were acquired on an LSRII cytometer (BD Biosciences)  
659 and data analysis was performed using FlowJo v10.7.1 (Tree Star). The specificity threshold was  
660 established using the following formula: (mean of pre-pandemic SARS-CoV-2 negative plasma +  
661 (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

662

#### 663 **Virus neutralization assay**

664 To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E-  
665 Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein  
666 (D614G, B.1.1.7, P.1, B.1.351, B.1.617.2, B.1.526 and SARS-CoV) at a ratio of 10:1. Two days  
667 post-transfection, cell supernatants were harvested and stored at -80°C until use. For the  
668 neutralization assay, 293T-ACE2 target cells were seeded at a density of  $1 \times 10^4$  cells/well in 96-  
669 well luminometer-compatible tissue culture plates (Perkin Elmer) 24h before infection.  
670 Pseudoviral particles were incubated with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250;  
671 1/31250) for 1h at 37°C and were then added to the target cells followed by incubation for 48h at  
672 37°C. Then, cells were lysed by the addition of 30  $\mu$ L of passive lysis buffer (Promega) followed  
673 by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to  
674 measure the luciferase activity of each well after the addition of 100  $\mu$ L of luciferin buffer (15mM  
675  $MgSO_4$ , 15mM  $KPO_4$  [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50  $\mu$ L of 1mM d-luciferin  
676 potassium salt (Prolume). The neutralization half-maximal inhibitory dilution ( $ID_{50}$ ) represents the  
677 plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

678

### 679 **SARS-CoV-2-specific B cells characterization**

680 To detect SARS-CoV-2-specific B cells, we conjugated recombinant RBD proteins with Alexa  
681 Fluor 488 or Alexa Fluor 594 (Thermo Fisher Scientific) according to the manufacturer's protocol.  
682 Approximately  $2 \times 10^6$  frozen PBMCs from SARS-CoV-2 naïve and prior infection donors were  
683 prepared in Falcon® 5ml-round bottom polystyrene tubes at a final concentration of  
684  $4 \times 10^6$  cells/mL in RPMI 1640 medium (GIBCO) supplemented with 10% of fetal bovine serum  
685 (Seradigm), Penicillin- Streptomycin (GIBCO) and HEPES (GIBCO). After a rest of 2h at 37°C  
686 and 5%  $CO_2$ , cells were stained using Aquavid viability marker (Biosciences) in DPBS (GIBCO)  
687 at 4°C for 20 min. The detection of SARS-CoV-2-antigen specific B cells was done by adding the  
688 RBD probes to the antibody cocktail (IgM BUV737, CD24 BUV805, IgG BV421, CD3 BV480,

689 CD56 BV480, CD14 BV480, CD16 BV480, CD20 BV711, CD21 BV786, HLA DR BB700, CD27  
690 APC R700; CD19 BV650, CD38 BB790, CD138 BUV661, CCR10 BUV395, IgD BUV563 and IgA  
691 PE). Staining was performed at 4°C for 30 min and cells were fixed using 1% paraformaldehyde  
692 (Sigma-Aldrich) at 4°C for 15 min. Stained PBMC samples were acquired on FACSymphony™  
693 A5 Cell Analyzer (BD Biosciences) and analyzed using FlowJo v10.7.1 software.

694

## 695 **QUANTIFICATION AND STATISTICAL ANALYSIS**

### 696 **Statistical analysis**

697 Symbols represent biologically independent samples from SARS-CoV-2 naïve individuals or  
698 SARS-CoV-2 PI individuals. Lines connect data from the same donor. Statistics were analyzed  
699 using GraphPad Prism version 8.0.1 (GraphPad, San Diego, CA). Every dataset was tested for  
700 statistical normality and this information was used to apply the appropriate (parametric or  
701 nonparametric) statistical test. Differences in responses for the same patient before and after  
702 vaccination were performed using Kruskal-Wallis tests. Differences in responses between naïve  
703 and PI individuals at each time point were measured by Mann-Whitney (V0, V1 and V2) or  
704 Kruskal-Wallis (V3) tests. Differences in responses against the different Spikes for the same  
705 patient were measured by Friedman tests. P values < 0.05 were considered significant;  
706 significance values are indicated as \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001.  
707 Spearman's R correlation coefficient was applied for correlations. Statistical tests were two-sided  
708 and p < 0.05 was considered significant.

709

### 710 **Software scripts and visualization**

711 Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph,  
712 tidyverse, and RColorBrewer packages (R; R studio). Edges are only shown if p < 0.05, and nodes

713 are sized according to the connecting edges'  $r$  values. Nodes are color-coded according to groups  
714 of parameters.

715

716 **SUPPLEMENTAL INFORMATION**

717 Supplemental information can be found online at ...



## 718 REFERENCES

- 719 Allen, H., Vusirikala, A., Flannagan, J., Twohig, K.A., Zaidi, A., Groves, N., Lopez-Bernal, J.,  
720 Harris, R., Charlett, A., Dabrera, G., et al. (2021). Increased Household Transmission of COVID-  
721 19 Cases Associated with SARS-CoV-2 Variant of Concern B.1.617.2: A national case-control  
722 study,  
723 <https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+C>  
724 [OVID-19+Cases+--+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa](https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+C). 21.
- 725 Anand, S.P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M.-J.,  
726 Lewin, A., Bazin, R., and Finzi, A. (2020). High-throughput detection of antibodies targeting the  
727 SARS-CoV-2 Spike in longitudinal convalescent plasma samples (Microbiology).
- 728 Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussièrès, G., Benlarbi, M., Gasser, R., Brassard,  
729 N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of humoral  
730 immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-  
731 symptom onset. *Cell Rep. Med.* 100290.
- 732 Annavajhala, M.K., Mohri, H., Wang, P., Nair, M., Zucker, J.E., Sheng, Z., Gomez-Simmonds, A.,  
733 Kelley, A.L., Tagliavia, M., Huang, Y., et al. (2021a). Emergence and Expansion of the SARS-  
734 CoV-2 Variant B.1.526 Identified in New York. *medRxiv* 2021.02.23.21252259.
- 735 Annavajhala, M.K., Mohri, H., Wang, P., Nair, M., Zucker, J.E., Sheng, Z., Gomez-Simmonds, A.,  
736 Kelley, A.L., Tagliavia, M., Huang, Y., et al. (2021b). A Novel and Expanding SARS-CoV-2  
737 Variant, B.1.526, Identified in New York. *MedRxiv* 2021.02.23.21252259.
- 738 Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector,  
739 S.A., Roupheal, N., Creech, C.B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-  
740 CoV-2 Vaccine. *N. Engl. J. Med.* 384, 403–416.
- 741 Beaudoin-Bussièrès, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,  
742 Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral Responses  
743 against SARS-CoV-2 Spike in Convalescent Individuals. *MBio* 11.
- 744 Beaudoin-Bussières, G., Chen, Y., Ullah, I., Prevost, J., Tolbert, W.D., Symmes, K., Ding, S.,  
745 Benlarbi, M., Gong, S.Y., Tauzin, A., et al. (2021). An anti-SARS-CoV-2 non-neutralizing antibody  
746 with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-  
747 hACE2 mice (Microbiology).
- 748 Brown, K.A., Tibebu, S., Daneman, N., Schwartz, K., Whelan, M., and Buchan, S. (2021).  
749 Comparative Household Secondary Attack Rates associated with B.1.1.7, B.1.351, and P.1  
750 SARS-CoV-2 Variants. *medRxiv* 2021.06.03.21258302.
- 751 CDC (2021). Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC,  
752 <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>.
- 753 Collier, D.A., De Marco, A., Ferreira, I.A.T.M., Meng, B., Datir, R.P., Walls, A.C., Kemp, S.A.,  
754 Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA  
755 vaccine-elicited antibodies. *Nature* 1–10.

- 756 Dagpunar, J. (2021). Interim estimates of increased transmissibility, growth rate, and reproduction  
757 number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. medRxiv  
758 2021.06.03.21258293.
- 759 Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I.,  
760 Haupt, S., Frazier, A., et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8  
761 months after infection. Science eabf4063.
- 762 Davies, N.G., Barnard, R.C., Jarvis, C.I., Kucharski, A.J., Munday, J., Pearson, C.A.B., Russell,  
763 T.W., Tully, D.C., Abbott, S., Gimma, A., et al. (2020). Estimated transmissibility and severity of  
764 novel SARS-CoV-2 Variant of Concern 202012/01 in England. MedRxiv 2020.12.24.20248822.
- 765 Davies, N.G., Abbott, S., Barnard, R.C., Jarvis, C.I., Kucharski, A.J., Munday, J.D., Pearson,  
766 C.A.B., Russell, T.W., Tully, D.C., Washburne, A.D., et al. (2021). Estimated transmissibility and  
767 impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372.
- 768 Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-  
769 19 in real time. Lancet Infect. Dis. 20, 533–534.
- 770 Doria-Rose, N., Suthar, M.S., Makowski, M., O’Connell, S., McDermott, A.B., Flach, B.,  
771 Ledgerwood, J.E., Mascola, J.R., Graham, B.S., Lin, B.C., et al. (2021). Antibody Persistence  
772 through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N. Engl. J. Med.  
773 384, 2259–2261.
- 774 ECDC (2021). Risk of spread of new SARS-CoV-2 variants of concern in the EU/EEA - first  
775 update, [https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-  
776 spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-risk-related-to-spread-of-new-SARS-CoV-2-variants-EU-EEA-first-update.pdf). 29.
- 777 Efrati, S., Catalogna, M., Abu Hamad, R., Hadanny, A., Bar-Chaim, A., Benveniste-Levkovitz, P.,  
778 and Levtzion-Korach, O. (2021). Safety and humoral responses to BNT162b2 mRNA vaccination  
779 of SARS-CoV-2 previously infected and naive populations. Sci. Rep. 11, 16543.
- 780 Fisman, D.N., and Tuite, A.R. (2021). Progressive Increase in Virulence of Novel SARS-CoV-2  
781 Variants in Ontario, Canada. medRxiv 2021.07.05.21260050.
- 782 Fraley, E., LeMaster, C., Banerjee, D., Khanal, S., Selvarangan, R., and Bradley, T. (2021).  
783 Cross-reactive antibody immunity against SARS-CoV-2 in children and adults. Cell. Mol. Immunol.  
784 18, 1826–1828.
- 785 Gaebler, C., Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A.,  
786 Jankovic, M., Schaefer-Babajew, D., Oliveira, T.Y., et al. (2021). Evolution of antibody immunity  
787 to SARS-CoV-2. Nature.
- 788 Gilbert, P.B., Montefiori, D.C., McDermott, A., Fong, Y., Benkeser, D., Deng, W., Zhou, H.,  
789 Houchens, C.R., Martins, K., Jayashankar, L., et al. (2021). Immune Correlates Analysis of the  
790 mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv 2021.08.09.21261290.
- 791 Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen,  
792 K.A., Reynaldi, A., Khoury, D.S., Pattekar, A., et al. (2021a). mRNA Vaccination Induces Durable  
793 Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern. bioRxiv  
794 2021.08.23.457229.

- 795 Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S.,  
796 Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021b). Distinct antibody and memory B cell  
797 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci.*  
798 *Immunol.* 6.
- 799 Goldberg, Y., Mandel, M., Bar-On, Y.M., Bodenheimer, O., Freedman, L., Haas, E.J., Milo, R.,  
800 Alroy-Preis, S., Ash, N., and Huppert, A. (2021). Waning immunity of the BNT162b2 vaccine: A  
801 nationwide study from Israel. *medRxiv* 2021.08.24.21262423.
- 802 Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D.,  
803 Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to selected  
804 SARS-CoV-2 emerging variants Spike antigenicity. *bioRxiv* 2021.08.04.455140.
- 805 Hicks, J., Klumpp-Thomas, C., Kalish, H., Shunmugavel, A., Mehalko, J., Denson, J.-P., Snead,  
806 K., Drew, M., Corbett, K., Graham, B., et al. (2020). Serologic cross-reactivity of SARS-CoV-2  
807 with endemic and seasonal Betacoronaviruses. *MedRxiv* 2020.06.22.20137695.
- 808 Hoffmann, M., Müller, M.A., Drexler, J.F., Glende, J., Erdt, M., Gützkow, T., Losemann, C., Binger,  
809 T., Deng, H., Schwegmann-Weßels, C., et al. (2013). Differential sensitivity of bat cells to infection  
810 by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses.  
811 *PLoS One* 8, e72942.
- 812 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens,  
813 T.S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2  
814 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 181, 271-280.e8.
- 815 Isabel, S., Graña-Miraglia, L., Gutierrez, J.M., Bundalovic-Torma, C., Groves, H.E., Isabel, M.R.,  
816 Eshaghi, A., Patel, S.N., Gubbay, J.B., Poutanen, T., et al. (2020). Evolutionary and structural  
817 analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. *Sci. Rep.*  
818 10, 14031.
- 819 Jackson, L.A., Anderson, E.J., Roupael, N.G., Roberts, P.C., Makhene, M., Coler, R.N.,  
820 McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., et al. (2020). An mRNA Vaccine  
821 against SARS-CoV-2 — Preliminary Report. *N. Engl. J. Med.* 383, 1920–1931.
- 822 JCVI (2021). Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary  
823 dose vaccination, [https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-](https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination)  
824 [dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-](https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination)  
825 [immunisation-jcvi-advice-on-third-primary-dose-vaccination](https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination).
- 826 Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K., Seydoux,  
827 E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and Characterization of Cross-  
828 Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. *bioRxiv* 2021.03.23.436684.
- 829 Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,  
830 Anand, S.P., et al. (2021). Structural Basis and Mode of Action for Two Broadly Neutralizing  
831 Antibodies Against SARS-CoV-2 Emerging Variants of Concern. *BioRxiv Prepr. Serv. Biol.*  
832 2021.08.02.454546.
- 833 Lozano-Ojalvo, D., Camara, C., Lopez-Granados, E., Nozal, P., Del Pino-Molina, L., Bravo-  
834 Gallego, L.Y., Paz-Artal, E., Pion, M., Correa-Rocha, R., Ortiz, A., et al. (2021). Differential effects


- 835 of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19  
836 recovered individuals. *Cell Rep.* 109570.
- 837 Meulen, J. ter, Brink, E.N. van den, Poon, L.L.M., Marissen, W.E., Leung, C.S.W., Cox, F.,  
838 Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., Deventer, E. van, et al. (2006). Human Monoclonal  
839 Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants.  
840 *PLOS Med.* 3, e237.
- 841 Moore, J.P., and Klasse, P.J. (2020). COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not  
842 Warped Minds. *J. Virol.* 94.
- 843 Muruato, A.E., Fontes-Garfias, C.R., Ren, P., Garcia-Blanco, M.A., Menachery, V.D., Xie, X., and  
844 Shi, P.-Y. (2020). A high-throughput neutralizing antibody assay for COVID-19 diagnosis and  
845 vaccine evaluation. *Nat. Commun.* 11, 4059.
- 846 Ng, K.W., Faulkner, N., Cornish, G.H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C.,  
847 Wrobel, A.G., Benton, D.J., et al. (2020). Preexisting and de novo humoral immunity to SARS-  
848 CoV-2 in humans. *Science* 370, 1339–1343.
- 849 Painter, M.M., Mathew, D., Goel, R.R., Apostolidis, S.A., Pattekar, A., Kuthuru, O., Baxter, A.E.,  
850 Herati, R.S., Oldridge, D.A., Gouma, S., et al. (2021). Rapid induction of antigen-specific CD4+ T  
851 cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2  
852 mRNA vaccination. *Immunity* S1074761321003083.
- 853 Park, J.-E., Li, K., Barlan, A., Fehr, A.R., Perlman, S., McCray, P.B., and Gallagher, T. (2016).  
854 Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus  
855 tropism. *Proc. Natl. Acad. Sci.* 113, 12262–12267.
- 856 Parry, H., Bruton, R., Stephens, C., Brown, K., Amirthalingam, G., Otter, A., Hallis, B., Zuo, J.,  
857 and Moss, P. (2021). Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after  
858 extended-interval homologous dual vaccination in older people. *Immun. Ageing A* 18, 34.
- 859 Pearson, C.A.B., Russell, T.W., Davies, N.G., Kucharski, A.J., CMMID COVID-19 working group,  
860 Edmunds, W.J., and Eggo, R.M. (2021). Estimates of severity and transmissibility of novel SARS-  
861 CoV-2 variant 501Y.V2 in South Africa, [https://cmmid.github.io/topics/covid19/sa-novel-](https://cmmid.github.io/topics/covid19/sa-novel-variant.html)  
862 [variant.html](https://cmmid.github.io/topics/covid19/sa-novel-variant.html).
- 863 Pilishvili, T. (2021). Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna  
864 COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021.  
865 *MMWR Morb. Mortal. Wkly. Rep.* 70.
- 866 Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais,  
867 C., Porrot, F., Robillard, N., Puech, J., et al. (2021a). Reduced sensitivity of SARS-CoV-2 variant  
868 Delta to antibody neutralization. *Nature* 596, 276–280.
- 869 Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C.,  
870 Buchrieser, J., Rajah, M.M., Bishop, E., et al. (2021b). Sensitivity of infectious SARS-CoV-2  
871 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat. Med.* 27, 917–924.

- 872 Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez  
873 Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA  
874 Covid-19 Vaccine. *N. Engl. J. Med.* 383, 2603–2615.
- 875 Prévost, J., and Finzi, A. (2021). The great escape? SARS-CoV-2 variants evading neutralizing  
876 responses. *Cell Host Microbe* 29, 322–324.
- 877 Prévost, J., Gasser, R., Beaudoin-Bussièeres, G., Richard, J., Duerr, R., Laumaea, A., Anand,  
878 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral  
879 Responses against SARS-CoV-2 Spike. *Cell Rep. Med.* 1, 100126.
- 880 Prévost, J., Richard, J., Gasser, R., Ding, S., Fage, C., Anand, S.P., Adam, D., Vergara, N.G.,  
881 Tausin, A., Benlarbi, M., et al. (2021). Impact of temperature on the affinity of SARS-CoV-2 Spike  
882 glycoprotein for host ACE2. *J. Biol. Chem.* 101151.
- 883 Puranik, A., Lenehan, P.J., Silvert, E., Niesen, M.J.M., Corchado-Garcia, J., O’Horo, J.C., Virk,  
884 A., Swift, M.D., Halamka, J., Badley, A.D., et al. (2021). Comparison of two highly-effective mRNA  
885 vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.
- 886 R R: a language and environment for statistical computing. [https://www.gbif.org/fr/tool/81287/r-a-](https://www.gbif.org/fr/tool/81287/r-a-language-and-environment-for-statistical-computing)  
887 [language-and-environment-for-statistical-computing.](https://www.gbif.org/fr/tool/81287/r-a-language-and-environment-for-statistical-computing)
- 888 R studio RStudio | Open source & professional software for data science teams.  
889 [https://rstudio.com/.](https://rstudio.com/)
- 890 Rabaan, A.A., Al-Ahmed, S.H., Haque, S., Sah, R., Tiwari, R., Malik, Y.S., Dhama, K., Yattoo,  
891 M.I., Bonilla-Aldana, D.K., and Rodriguez-Morales, A.J. (2020). SARS-CoV-2, SARS-CoV, and  
892 MERS-COV: A comparative overview. *Infez. Med.* 28, 174–184.
- 893 Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock,  
894 T., Robertson, D.L., and Volz, E. (2020). Preliminary genomic characterisation of an emergent  
895 SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations - SARS-CoV-2  
896 coronavirus / nCoV-2019 *Genomic Epidemiology*.
- 897 Sabino, E.C., Buss, L.F., Carvalho, M.P.S., Prete, C.A., Crispim, M.A.E., Fraiji, N.A., Pereira,  
898 R.H.M., Parag, K.V., Peixoto, P. da S., Kraemer, M.U.G., et al. (2021). Resurgence of COVID-19  
899 in Manaus, Brazil, despite high seroprevalence. *The Lancet* 397, 452–455.
- 900 Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A., Pascal,  
901 K., Quandt, J., Maurus, D., et al. (2020). COVID-19 vaccine BNT162b1 elicits human antibody  
902 and T H 1 T cell responses. *Nature* 586, 594–599.
- 903 Sarkar, J.P., Saha, I., Seal, A., Maity, D., and Maulik, U. (2021). Topological Analysis for  
904 Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19  
905 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV. *Infect. Genet. Evol.* 88,  
906 104708.
- 907 Skowronski, D., and De Serres, G. (2021). Safety and Efficacy of the BNT162b2 mRNA Covid-19  
908 Vaccine. *N. Engl. J. Med.* NEJMc2036242.











- 909 Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M.,  
910 Seydoux, E., Jennewein, M.F., MacCamy, A.J., et al. (2021). mRNA vaccination boosts cross-  
911 variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science* eabg9175.
- 912 Tang, J.W., Toovey, O.T.R., Harvey, K.N., and Hui, D.S.C. (2021). Introduction of the South  
913 African SARS-CoV-2 variant 501Y.V2 into the UK. *J. Infect.* 82, e8–e10.
- 914 Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., Frankland,  
915 T.B., Ogun, O.A., Zamparo, J.M., Gray, S., et al. (2021). Six-Month Effectiveness of BNT162B2  
916 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study  
917 (Rochester, NY: Social Science Research Network).
- 918 Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussi eres, G., Brassard,  
919 N., Laumaea, A., V ezina, D., Pr evost, J., et al. (2021). A single dose of the SARS-CoV-2 vaccine  
920 BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. *Cell Host Microbe*  
921 0.
- 922 Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D.,  
923 Pillay, S., San, E.J., Msomi, N., et al. (2020). Emergence and rapid spread of a new severe acute  
924 respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations  
925 in South Africa. *MedRxiv* 2020.12.21.20248640.
- 926 Ullah, I., Pr evost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussi eres, G.,  
927 Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in mice  
928 reveals that neutralizing antibodies require Fc function for optimal efficacy. *Immunity* S1074-  
929 7613(21)00347-2.
- 930 Urbanowicz, R.A., Tsoleridis, T., Jackson, H.J., Cusin, L., Duncan, J.D., Chappell, J.G., Tarr,  
931 A.W., Nightingale, J., Norrish, A.R., Ikram, A., et al. (2021). Two doses of the SARS-CoV-2  
932 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-  
933 2 infection. *Sci. Transl. Med.* eabj0847.
- 934 Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley, W.R., Laydon,  
935 D.J., Dabrera, G., O'Toole,  ., et al. (2021). Transmission of SARS-CoV-2 Lineage B.1.1.7 in  
936 England: Insights from linking epidemiological and genetic data. *MedRxiv* 2020.12.30.20249034.
- 937 Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P.,  
938 Hatipoglu, E., Ngai, Y., et al. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs  
939 B.1.617.2 and B.1.351 by BNT162b2 vaccination. *The Lancet* 397, 2331–2333.
- 940 Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veessler, D. (2020). Structure,  
941 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 181, 281-292.e6.
- 942 Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong,  
943 P.D., et al. (2021a). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
- 944 Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H.-  
945 H., Barnes, C.O., Cipolla, M., Ramos, V., et al. (2021b). Naturally enhanced neutralizing breadth  
946 against SARS-CoV-2 one year after infection. *Nature* 595, 426–431.

- 947 WHO (2021). Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine,  
948 BNT162b2, under Emergency Use Listing, <https://www.who.int/publications/i/item/WHO-2019->  
949 [nCoV-vaccines-SAGE\\_recommendation-BNT162b2-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1).
- 950 World Health Organization WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int>.
- 951



- Naïve (2 doses, long interval)
- Previously infected (2 doses, long interval)
- Previously infected (1 dose)



**Figure 1**



● Naïve (2 doses, long interval)    ● It had previously infected (2 doses, long interval)    ● Previously infected (1 dose)






Figure 2

● Naïve (2 doses, long interval)    ● Previously infected (2 doses, long interval)    ● Previously infected (1 dose)

**A**



**B**




**Figure 3**


● Naïve (2 doses, long interval)    ● Previously infected (2 doses, long interval)    ● Previously infected (1 dose)

**A**

**B.1.1.7**




**B.1.1.7**




**B**

**B.1.351**




**B.1.351**




**C**

**B.1.617.2**




**B.1.617.2**




**D**

**P.1**




**P.1**




**E**

**B.1.526**




**B.1.526**




**F**



**SARS-CoV-1**







**SARS-CoV-1**



**Figure 4**







**Figure 5**



**Figure 6**

● Naïve (2 doses, long interval)  
● Previously infected (1 dose)

● Previously infected (2 doses, long interval)  
● Naïve (2 doses, short interval)




**Figure S1 : Recognition of SARS-CoV-2 Spike variants and *hCoronaviruses* Spike by plasma from naïve and PI donors at each time point, Related to Figure 2 and 5.**

293T cells were transfected with the indicated Betacoronavirus Spike and stained with the CV3-25 Ab or with plasma collected at V0 (A), V1 (B), V2 (C) and V3 (D) and analyzed by flow cytometry. Plasma recognitions are normalized with CV3-25 binding. Naïve and PI donors with a long interval between the two doses are represented by red and black points respectively, PI donors who received just one dose by blue points and naïve donors with a short interval between the two doses by green points. Error bars indicate means  $\pm$  SEM. (\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ ; \*\*\*\*  $P < 0.0001$ ; ns, non-significant).



● Naïve (2 doses, long interval)  
● Previously infected (1 dose)

● Previously infected (2 doses, long interval)  
● Naïve (2 doses, short interval)



**Figure S2 : Neutralization of SARS-CoV-2 Spike variants and SARS-CoV-1 Spike by plasma from naïve and PI donors at each time point, Related to Figures 3, 4 and 5.**

Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S variant or SARS-CoV-1 S glycoproteins, with serial dilutions of plasma collected at V0 (A), V1 (B), V2 (C) and V3 (D) for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were determined using a normalized non-linear regression using GraphPad Prism software. Naïve and PI donors with a long interval between the two doses are represented by red and black points respectively, PI donors who received just one dose by blue points and naïve donors with a short interval between the two doses by green points. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM. (\* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001; ns, non-significant).